Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa.

Naveen Karthik, Syeda Fatima Abid, Yuxi Zheng, Miguel Materin, Xi Chen

Abstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Naveen KarthikDuke Eye Center, 2351 Erwin Rd, Durham, NC, 27705, USA.

Syeda Fatima AbidDuke Eye Center, 2351 Erwin Rd, Durham, NC, 27705, USA.

Yuxi ZhengDuke Eye Center, 2351 Erwin Rd, Durham, NC, 27705, USA.

Miguel MaterinDuke Eye Center, 2351 Erwin Rd, Durham, NC, 27705, USA.

Xi ChenDuke Eye Center, 2351 Erwin Rd, Durham, NC, 27705, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To report a case of exudative retinopathy secondary to retinal vasoproliferative tumor (RVPT) refractory to aflibercept treated with faricimab-svoa (faricimab). Principal results: A 43-year-old female presented with an exudative and hemorrhagic lesion in the periphery of the right eye consistent with RVPT. She was treated initially with three aflibercept injections every 4-6 weeks. Despite treatment, her exam worsened with increased exudation and subretinal fluid. She was then treated with five monthly faricimab injections, which resulted in resolution of subretinal fluid and exudates, and near complete regression of the RVPT. The patient subsequently developed a retinal tear at the base of the RVPT that was successfully treated with laser retinopexy. At one year follow-up, the RVPT remained fully regressed. She was monitored off therapy. No adverse event was noted. Conclusions: Faricimab has potential utility in treating exudative retinopathy secondary to RVPT. Further investigation with treatment trials and long-term follow-up is warranted.

Indexed as

AfliberceptExudative retinal detachmentExudative retinopathyFaricimab-svoaRetinal vasoproliferative tumor

Identifiers

PMID42158565

DOI10.1016/j.ajoc.2026.102593

PMCPMC13182779

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.